Dr. Carlos Doti Explains How AstraZeneca's Lynparza Has Impacted Oncology

When AstraZeneca’s first PARP inhibitor, lynparza (olaparib), was approved by the US Food and Drug Administration in 2014, it marked the start of a new era of oncology leadership for the company. Since that approval, 8 new AstraZeneca cancer therapies—which treat many different types of cancers, including lung, liver, breast, and more—have come to market. The company has bold ambitions in cancer care, with the goal of treating some of the hardest to treat cancers. This year, lynparza, which has been used to treat approximately 140,000 patients worldwide, celebrates 10 years of being on the market.

DocWire News spoke with Carlos Doti, MD, Vice President, Head of Medical Affairs, US Oncology Business Unit. at AstraZeneca, about the scientific innovations behind lynparza and the impact the therapy has had over the last decade.